Access to COVID-19 vaccines: Global approaches in a global c

Access to COVID-19 vaccines: Global approaches in a global crisis


Access to COVID-19 vaccines: Global approaches in a global crisis

Abstract
Following the extraordinarily rapid development of COVID‑19 vaccines, immunisation is underway in many OECD countries. However, demand will continue to outstrip supply for some time and currently, distribution is strongly skewed in favour of high-income countries. This both inequitable and inefficient. Directing vaccine to where need is greatest would maximise the number of lives saved and speed bringing the pandemic under control, by slowing transmission and reducing the likelihood of the emergence of viral variants of concern. Governments should therefore act now to accelerate vaccination globally, regardless of international borders, by reallocating supplies to areas of greatest need; continuing the scaling-up of production; ensuring that necessary logistics and health care infrastructure are in place; providing further financial and in-kind support to COVAX; and developing long-term strategies that include commitments to making vaccines available where they are needed most, including through sharing intellectual property and facilitating technology transfer.

Related Keywords

Morocco , Israel , Australia , Serbia , Kazakhstan , Afghanistan , United States , Paris , France General , France , United Kingdom , Belarus , Brazil , China , Russia , Bahrain , Amsterdam , Noord Holland , Netherlands , Mexico , New Zealand , India , Turkmenistan , Ghana , Poland , Switzerland , Malaysia , Japan , Algeria , Argentina , Bolivia , Washington , South Africa , Colombia , Indonesia , United Arab Emirates , Canada , Pakistan , London , City Of , Germany , Denmark , Costa Rica , Singapore , Paraguay , Geneva , Genè , Saudi Arabia , Chile , Sinovac , 00 , Venezuela , Turkey , America , Chinese , Bharat , Palestinian , Urlreferences Dagan , Doireferences Polack , Doireferences Bown , Astrazeneca Oxford , Urlreferences Lloyd Sherlock , Doireferences Mallapaty , Urlreferences Cohen , Urlreferences Cakmakli , Anhui Zhifei Longcom , Urlreferences Zhang , Institut Pasteur Themis Merck , Oxford Astrazeneca Chadox , Doireferences Burton , Doireferences Voysey , Doireferences Weekes , Doireferences Grenfell , Doireferences Callaway , Oxford Astrazeneca , Doireferences Baden , Urlreferences Manisty , Doireferences Prendecki , November Zhang , Urlreferences Gavi , Doireferences Dai , Nature Research , University Of Queensland , Authorea Inc , World Trade Organization , Pfizer , Knowledge Network On Innovation , Astrazeneca , Sinopharm Beijing Institute , Serum Institute , Sinovac Life Sciences , Drug Administration , European Commission , World Health Organization , Sinopharm Wuhan Institute , Palestinian Authority , Clover Pharmaceuticals , Chinese Academy Of Medical Sciences , Ministries Of Health , International Production Networks , Novartis , Centre For Economic Policy Research , Vaccine Centre , Research Institute For Biological Safety Problems , European Union , Gameleya Institute Russia , Peterson Institute For International Economics , Serum Institute Of India , Oxford University , Novavax Inc , References Knowledge Network On Innovation , Doireferences Israel Ministry Of Health , Access Consortium , Global Health Centre , Technology Access Pool , European Medicines Agency , Johnson , Doireferences Novavax Inc , Therapeutic Goods Administration , Gameleya Institute , Access Pool , Evolutionary Dynamics , Emergency Use Authorizations , Guide Medical Product Developers Addressing Virus , Economist Intelligence Unit , South America , Knowledge Network , While Canada , Arab Emirates , Latin America , Emergency Use Authorization , Emergency Use , Cansino Biologics , Life Sciences , Infectious Diseases , Anges Inc , Japan Agency , Zhifei Longcom Biologic , Indian Council , National Institute , Bharat Biotech , Medical Sciences , Biological Safety Problems , Confirms High Levels , Efficacy Against Original , Molecular Clamp Vaccine , References Mallapaty , Israel Ministry , Nationwide Mass Vaccination , New England Journal , The Context Of Limited Supply , Demographic Characteristics , People Receiving , Peterson Institute , International Economics , Economic Case , Global Vaccinations , International Production , Economic Policy Research , Interim Report March , References Knowledge Network , Manufacturing Arrangements , Graduate Institute , Use Authorization , Lancet Infectious Diseases , Novavax Confirms High Levels , South Africa Trials , மொராக்கோ , இஸ்ரேல் , ஆஸ்திரேலியா , செர்பியா , காஸக்ஸ்டாந் , ஒன்றுபட்டது மாநிலங்களில் , பாரிஸ் , பிரான்ஸ் ஜநரல் , பிரான்ஸ் , ஒன்றுபட்டது கிஂக்டம் , பெலாரஸ் , பிரேசில் , சீனா , ரஷ்யா , பஹ்ரைன் , ஆம்ஸ்டர்டாம் , நூற்த் ஹாலண்ட் , நெதர்லாந்து , மெக்ஸிகோ , புதியது ஜீலாந்து , இந்தியா , டர்க்மெனிஸ்தான் , கானா , போல்யாஂட் , சுவிட்சர்லாந்து , மலேசியா , ஜப்பான் , அல்ஜீரியா , அர்ஜெண்டினா , பொலிவியா , வாஷிங்டன் , கொலம்பியா , இந்தோனேசியா , ஒன்றுபட்டது அரபு அமீரகங்கள் ,

© 2025 Vimarsana